Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential encorafenib + binimetinib followed by nivolumab + ipilimumab versus nivolumab + ipilimumab alone in BRAF V600-mutant advanced melanoma
NL-OMON58754Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of encorafenib, binimetinib, nivolumab and ipilimumab in melanoma (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Jun 2019; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON58754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58754.